



DEVONIAN HEALTH GROUP INC.

**PRESS RELEASE**

*For immediate release*

## **DEVONIAN HEALTH GROUP INC. RETAINS RENMARK FINANCIAL COMMUNICATIONS INC. TO PROVIDE INVESTOR RELATIONS SERVICES**

**QUEBEC, April 14, 2021 – Devonian Health Group Inc. (“Devonian” or the “Corporation”)** (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that it has retained the services of Renmark Financial Communications Inc. to handle its investor relations activities.

“We are pleased to announce that we have selected Renmark to reinforce Devonian Health's profile in the financial community and enhance the visibility of our company. We choose Renmark because its standards and methodologies fit best with the message we wish to communicate to the investing public,” noted Andre P. Boulet, PhD., President & Chief Executive Officer.

In consideration of the services to be provided, the monthly fees incurred by Devonian Health Group Inc. will be a cash consideration of up to \$8,000 CAD, starting May 1st, 2021 for a period of six months ending on October 31st, 2021 and monthly thereafter.

Renmark Financial Communications does not have any interest, directly or indirectly, in Devonian Health Group Inc. or its securities, or any right or intent to acquire such an interest.

### **For further information, please contact:**

Dr. Andre P. Boulet, PhD  
President and Chief Executive Officer  
Tel: (514) 248-7509  
Email: [apboulet@groupe-devonian.com](mailto:apboulet@groupe-devonian.com)

### **Renmark Financial Communications Inc.**

Scott Logan: [slogan@renmarkfinancial.com](mailto:slogan@renmarkfinancial.com)  
Tel: (416) 644-2020 or (212) 812-7680  
[www.renmarkfinancial.com](http://www.renmarkfinancial.com)

### **About Devonian**

Devonian Health Group Inc. is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over



those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Devonian is traded publicly on the TSXV Exchange (TSXv:GSD).

For more information, visit [www.groupedevonian.com](http://www.groupedevonian.com)

### **Forward Looking Statements**

This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21<sup>st</sup>, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*